Compare ACRS & BLMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACRS | BLMN |
|---|---|---|
| Founded | 2012 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Restaurants |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 608.9M | 714.0M |
| IPO Year | 2015 | 2012 |
| Metric | ACRS | BLMN |
|---|---|---|
| Price | $5.35 | $8.60 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 8 |
| Target Price | ★ $10.20 | $7.88 |
| AVG Volume (30 Days) | 2.0M | ★ 2.2M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 4.99% |
| EPS Growth | 69.01 | ★ 106.71 |
| EPS | N/A | ★ 0.65 |
| Revenue | $1,683,000.00 | ★ $4,213,346,000.00 |
| Revenue This Year | N/A | $2.07 |
| Revenue Next Year | $4.24 | $1.81 |
| P/E Ratio | ★ N/A | $12.99 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.46 | $5.19 |
| 52 Week High | $5.85 | $10.70 |
| Indicator | ACRS | BLMN |
|---|---|---|
| Relative Strength Index (RSI) | 55.46 | 56.58 |
| Support Level | $4.13 | $7.06 |
| Resistance Level | $5.85 | $8.70 |
| Average True Range (ATR) | 0.31 | 0.50 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 50.00 | 57.28 |
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.
Bloomin Brands Inc is a casual dining restaurant company, with a portfolio of, differentiated restaurant concepts. Its restaurant portfolio includes Outback Steakhouse, Carrabba's Italian Grill, Bonefish Grill and Fleming's Prime Steakhouse & Wine Bar. Its restaurant concepts range in price point and degree of formality from casual (Outback Steakhouse and Carrabba's Italian Grill) to polished casual (Bonefish Grill) and fine dining (Fleming's Prime Steakhouse & Wine Bar). The U.S. segment includes all restaurants operating in the U.S. while franchised restaurants operating outside the U.S. are included in the international franchise segment.